Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
186
Enrollment
INDUSTRY
Sponsor class

Stopped Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.

Conditions

Interventions

Sponsor

Aerovate Therapeutics